Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC

Article ID	Journal	Published Year	Pages	File Type
3204822	Journal of the American Academy of Dermatology	2015	14 Pages	PDF

Abstract

The 12-month update of the study confirms the efficacy and safety of vismodegib in management of advanced BCC.

Keywords

BCC FDA metastatic basal cell carcinoma advanced basal cell carcinoma IRF PFs TEAE US Food and Drug Administration progression-free survival DOR adverse event treatment-emergent adverse event confidence interval duration of response hedgehog pathway inhibitor vismodegib Basal cell carcinoma

Related Topics

Health Sciences Medicine and Dentistry Dermatology

Preview

Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC

Authors

Aleksandar MD, Michael R. MD, Karl MD, John D. MD, James A. MD, PhD, Simon MD, Sarah T. MD, PhD, Philip A. MD, PhD, Ellen MD, Charles M. MD, PhD, Anne Lynn S. MD, Luc MD, PhD, Jeannie MD, Huibin PhD, Axel MD,